Douglas E. Feldman, PhD

Research Assistant Professor of Pathology (Part-Time)

Image of Douglas E. Feldman, PhD
Is this your profile? Click to edit

Overview

Dr. Feldman’s research team studies the following major topic areas:

1. Immunomodulation and immune engineering for the treatment of inflammation and fibrosis.
2. Roles of modified DNA bases in immune signaling and gene control.
2. Functional analysis of viral counter-immune systems.

Categories: Gene Control, Stem Cells, Cancer, Epigenetics, DNA modification, immune engineering, immunotherapy, fibrosis, AALD

Education and Training

  • Harvard College, Cambridge, MA. — A.B. Magna cum laude — Biochemistry
  • Stanford University, Stanford, CA. — Ph.D — Molecular Cell Biology

Research Funding

  • Activation of NK cell-mediated protective immunity for the systemic treatment of ALD
    NIH · R21AA029741 · Sep 11, 2023 – Aug 31, 2025 · Role: Principal Investigator
  • Activation of NK cell-mediated protective immunity for the systemic treatment of ALD
    NIH · 1R21AA029741-01A1 · Sep 1, 2023 – Aug 31, 2025 · Role: PI
  • STING-Activating CAR-NK Cell Therapy
    US DOD CDMRP · Aug 15, 2022 – Feb 14, 2024 · Role: PI
  • Engineering CAR-T for treatment of alcoholic liver disease
    NIH · R21AA027535 · Sep 20, 2019 – Aug 31, 2021 · Role: PI
  • Robert E. and May R. Wright Foundation Trust
    Robert E. and May R. Wright Foundation Trust
  • American Cancer Society
    American Cancer Society
  • James H. Zumberge Faculty Research and Innovation Fund
    James H. Zumberge Faculty Research and Innovation Fund

Publications

  • Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest. 2024 10 01; 134(19).. View in PubMed
  • MSI2 promotes translation of multiple IRES-containing oncogenes and virus to induce self-renewal of tumor initiating stem-like cells. Cell Death Discov. 2023 Apr 28; 9(1):141.. View in PubMed
  • Bacteriophage antidefense genes that neutralize TIR and STING immune responses. Cell Rep. 2023 04 25; 42(4):112305.. View in PubMed
  • HMCES Functions in the Alternative End-Joining Pathway of the DNA DSB Repair during Class Switch Recombination in B Cells. Mol Cell. 2020 01 16; 77(2):384-394.e4.. View in PubMed
  • An Adversarial DNA N6-Methyladenine-Sensor Network Preserves Polycomb Silencing. Mol Cell. 2019 06 20; 74(6):1138-1147.e6.. View in PubMed
  • Erasure of Tet-Oxidized 5-Methylcytosine by a SRAP Nuclease. Cell Rep. 2017 Oct 10; 21(2):482-494.. View in PubMed
  • Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest. 2013 Jul; 123(7):2832-49.. View in PubMed
  • The TBC1D15 oncoprotein controls stem cell self-renewal through destabilization of the Numb-p53 complex. PLoS One. 2013; 8(2):e57312.. View in PubMed
  • Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J Gastroenterol Hepatol. 2012 Mar; 27.. View in PubMed
  • Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A. 2012 Jan 17; 109(3):829-34.. View in PubMed
  • Hypoxia and the unfolded protein response. Methods Enzymol. 2007; 435:275-93.. View in PubMed
  • Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiae. Mol Cancer Res. 2005 Dec; 3(12):669-77.. View in PubMed
  • The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res. 2005 Nov; 3(11):597-605.. View in PubMed
  • Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. Mol Cell. 2003 Nov; 12(5):1213-24.. View in PubMed